Trials / Unknown
UnknownNCT04252365
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
A Randomized Controlled, Phase II Trial Comparing Sintilimab and Pembrolizumab at First-line Setting in Patients With Advanced Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Guangdong Association of Clinical Trials · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center, randomized controlled, phase II clinical trial, aiming at giving a comparison of Sintilimab and Pembrolizumab in stage IIIB-IV NSCLC patients at first-line treatment setting.
Detailed description
This trial has been set up with two arms. Screened patients would be included into one of the arms based on tumor PD-L1 expression. The purpose of this study is to compare the efficacy of the approved checkpoint inhibitor pembrolizumab and home-made drug Sintilimab in patients with advanced NSCLC whose tumor have high PD-L1 expression and low or negative expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | Given i.v. |
| DRUG | Pembrolizumab | Given i.v. |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2021-03-01
- Completion
- 2021-12-01
- First posted
- 2020-02-05
- Last updated
- 2020-02-05
Source: ClinicalTrials.gov record NCT04252365. Inclusion in this directory is not an endorsement.